Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME

v3.24.2.u1
CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME - USD ($)
shares in Thousands, $ in Thousands
12 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2022
CONSOLIDATED STATEMENTS OF EARNINGS AND COMPREHENSIVE INCOME      
Net sales $ 1,159,060 $ 1,136,702 $ 1,105,599
Cost of sales 389,335 366,887 349,103
Gross margin 769,725 769,815 756,496
Operating expenses:      
Selling, general and administrative 466,375 378,378 372,766
Research and development 96,664 92,493 87,140
Total operating expenses 563,039 470,871 459,906
Operating income 206,686 298,944 296,590
Interest expense (15,736) (11,215) (11,309)
Interest income 3,323 3,410 794
Other non-operating income (expense), net (8,584) 47,520 15,311
Total other income (expense), net (20,997) 39,715 4,796
Earnings before income taxes 185,689 338,659 301,386
Income taxes 17,584 53,217 38,287
Net earnings, including noncontrolling interest 168,105 285,442 263,099
Net earnings attributable to noncontrolling interest   179 (8,952)
Net earnings attributable to Bio-Techne 168,105 285,263 272,051
Other comprehensive income (loss):      
Foreign currency translation income (loss) (7,492) 4,191 (32,241)
Foreign currency translation reclassified to earnings with Eminence deconsolidation   119  
Unrealized gains (losses) on derivative instruments - cash flow hedges, net of tax amounts disclosed in Note 8 (4,760) 4,793 14,262
Other comprehensive income (loss) (12,252) 9,103 (17,979)
Other comprehensive income (loss) attributable to noncontrolling interest   (33) (70)
Total other comprehensive income (loss), net of tax (12,252) 9,136 (17,909)
Comprehensive income attributable to Bio-Techne $ 155,853 $ 294,399 $ 254,142
Earnings per share attributable to Bio-Techne:      
Basic (in dollars per share) $ 1.07 $ 1.81 $ 1.73
Diluted (in dollars per share) $ 1.05 $ 1.76 $ 1.66
Weighted average common shares outstanding:      
Basic (in shares) 157,708 157,179 156,874
Diluted (in shares) 160,774 161,855 164,114